Ra Pharma Strengthens Senior Management Team

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ra Pharmaceuticals today announced two senior management appointments, Dr. Jeffrey Johnston as Senior Vice President and Chief Medical Officer and Mr. David Lubner as Chief Financial Officer and Executive Vice President, Operations.

"2015 was a breakthrough year for Ra, which included the closing of our $59M Series B financing, expanding our investor syndicate with industry leading healthcare investors, as well as the initiation of the Phase 1 study of our synthetic peptide C5 inhibitor, RA101495," said Doug Treco, PhD, Founder and CEO of Ra Pharmaceuticals. "We are excited to have Jeff and David join our team and build on the momentum created in 2015 as we transform Ra into a successful clinical-stage biotechnology company and move our pipeline programs forward in 2016." RA101495 is being developed for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare hemolytic syndrome, as well as other complement-based disorders.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.

ATAI Life Sciences is topping off a busy year with a $125 million financing, which will push two programs through phase 2 readouts.

After more than a decade working on heart failure programs with Cytokinetics, Amgen is handing two programs back to its partner.